IOL-VIP system: new hope for low vision patients

Article

Besides external magnifying glasses, certain intraocular lenses and devices have been proposed as feasible visual aids for AMD patients.

Key Points

Hereditary or acquired macular degeneration causes severe central vision loss and, in spite of several new therapeutic procedures, reduces the capability of patients to perform day-to-day activities, such as reading, writing, and precise handling. Importantly, it can lead to legal blindness.

Once central vision has been lost, optical devices that increase retinal image size by angular magnification offer the only chance of improving visual function. Besides external magnifying lenses, certain intraocular lenses (IOL) and devices have been proposed as feasible visual aids in these patients.

The first is the Hanita implant, which has a central hyper-minus lens, associated with a spectacle hyperpositive lens. The second is the Implantable Miniature Telescope (IMT); a quartz glass telescope prosthesis, which is implanted monocularly to give one eye improved central vision, while the other eye is left alone to continue to provide peripheral vision for orientation and mobility. Both devices improve retinal image size, but significantly reduce peripheral visual field, thus hampering everyday activities. A third option is the IOL-VIP (Intraocular Lens for Visually Impaired People) system, which consists of both a surgical and a rehabilitation approach designed ultimately to improve vision capabilities in maculopathy patients.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
Related Content
© 2024 MJH Life Sciences

All rights reserved.